Àΰ£ °áÇÙ ¹é½Å ½ÃÀå : À¯Çüº°, ¿¬·ÉÃþº°, À¯Åë ä³Îº°, Áö¿ªº°
Human Tuberculosis Vaccine Market, By Type, By Age Group, By Distribution Channel, By Geography
»óǰÄÚµå : 1674200
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,385,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,933,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,191,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Àΰ£ °áÇÙ ¹é½Å ¼¼°è ½ÃÀåÀº 2025³â¿¡´Â 6,810¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 1¾ï 240¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2032³â µ¿¾È 6.0%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í¼­ ¹üÀ§ º¸°í¼­ »ó¼¼ ³»¿ë
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 6,810¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR 6.00% 2032³â °¡Ä¡ ¿¹Ãø 1¾ï 240¸¸ ´Þ·¯
±×¸². Àΰ£ °áÇÙ ¹é½Å ½ÃÀå Á¡À¯À²(%), 2025³â, Áö¿ªº°
Human Tuberculosis Vaccine Market-IMG1

°áÇÙÀº Ä¡·á¿Í ¿¹¹æÀÌ °¡´ÉÇÑ Áúº´ÀÓ¿¡µµ ºÒ±¸ÇÏ°í ¿©ÀüÈ÷ ¼¼°è 10´ë »ç¸Á ¿øÀÎ Áß ÇϳªÀÔ´Ï´Ù. ÇöÀç ³Î¸® »ç¿ëµÇ°í ÀÖ´Â °áÇÙ ¹é½ÅÀº BCG(Bacillus Calmette-Gelin) ¹é½Å»ÓÀ̸ç, ¿¹¹æ È¿°ú°¡ Á¦ÇÑÀûÀÌ°í ¼Ò¾Æ¿¡°Ô¸¸ ±ÇÀåµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°è °áÇÙ ºÎ´ãÀ» ¾ïÁ¦Çϱâ À§Çؼ­´Â »õ·Ó°í È¿°úÀûÀÎ ¹é½ÅÀÇ °³¹ßÀÌ ½Ã±ÞÇÕ´Ï´Ù. °áÇÙ±ÕÀÇ »ý¾ÖÁÖ±âÀÇ ´Ù¾çÇÑ ´Ü°è¸¦ ´ë»óÀ¸·Î ÇÏ´Â ¿©·¯ ¹é½Å Èĺ¸¹°ÁúÀÌ ÀÓ»ó½ÃÇè Áß¿¡ ÀÖ½À´Ï´Ù. Æó°áÇÙÀÇ Áúº´°ú ÀüÆÄ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¹æ¾î·ÂÀ» Á¦°øÇÏ´Â ¹é½ÅÀº ÀÌ ¿À·¡µÈ º´¿ø±ÕÀ» ÅðÄ¡Çϱâ À§ÇÑ ³ë·Â¿¡ ÀÖ¾î °ÔÀÓ Ã¼ÀÎÀú°¡ µÉ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°è Àΰ£ °áÇÙ ¹é½Å ½ÃÀåÀº ÁÖ·Î ¼¼°è °áÇÙ ÁúȯÀÇ Áö¼ÓÀûÀÎ ºÎ´ã¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖÀ¸¸ç, 2025³â 10¿ù 29ÀÏ, WHO¿¡ µû¸£¸é 2025³â ÃÑ 125¸¸ ¸íÀÌ °áÇÙÀ¸·Î »ç¸ÁÇß½À´Ï´Ù. °áÇÙÀº Äڷγª ¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)¿¡ ÀÇÇØ ´ëüµÈ Áö 3³â ¸¸¿¡ ´Ù½Ã ´ÜÀÏ °¨¿°À¸·Î ÀÎÇÑ »ç¸Á ¿øÀÎ Áß ¼¼°è 1À§·Î º¹±ÍÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. Áø´Ü¹ý°ú ¹é½ÅÀÇ °³¼±ÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ ±¹Á¦º¸°Ç±â±¸´Â °áÇÙ ¹é½Å ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ÇöÀç 15°³ ÀÌ»óÀÇ ¹é½Å È帰¡ ´Ù¾çÇÑ ´Ü°èÀÇ ÀÓ»ó½ÃÇè ´Ü°è¿¡ ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº °³¹ß ºñ¿ë°ú ±ÔÁ¦ À庮ÀÌ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. °úÇÐÀÚµéÀº °áÇÙ ¹é½ÅÀÇ È¿´É, ¾ÈÀü¼º, Á¦Á¶ ¿ëÀ̼ºÀ» °³¼±Çϱâ À§ÇØ mRNA Ç÷§Æû°ú °°Àº »õ·Î¿î ±â¼úÀ» ¸ð»öÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº Àεµ, Áß±¹ µîÀÇ ±¹°¡¿¡¼­ °áÇÙ À¯º´·üÀÌ ³ô±â ¶§¹®¿¡ °¡Àå Å« ½ÃÀåÀÔ´Ï´Ù. È¿°úÀûÀÎ ¹é½ÅÀ» °³¹ßÇϸé Áúº´ ÀüÆÄ¸¦ ¾ïÁ¦Çϰí, ºÎ´ãÀÌ Å« ÀÇ·á ½Ã½ºÅÛ¿¡ Å« ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¼¼°èÀÇ Àΰ£ °áÇÙ ¹é½Å ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â)ÀÇ ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

¼¼°è Àΰ£ °áÇÙ ¹é½Å ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» ±â¾÷ °³¿ä, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅ͸¦ ±âÁØÀ¸·Î Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

º» Á¶»ç ´ë»óÀÇ ÁÖ¿ä ±â¾÷¿¡´Â GSK plc., Serum Institute of India Pvt. Ltd., Valneva SE, Archivel Farma, BIOFABRI (Zendal), Japan BCG Laboratory, CSL Seqirus, GreenSignal Bio Pharma Private Limited (GSBPL), AJ Vaccines A/S, Taj Pharmaceuticals Ltd., Merck & Co., Inc., Bharat Biotech, Moderna, Inc., BioNTech SE µîÀÌ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

Àΰ£ °áÇÙ ¹é½Å ¼¼°è ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ÁøÀÔÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è Àΰ£ °áÇÙ ¹é½Å ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú °¡Á¤

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå Àΰ£ °áÇÙ ¹é½Å ½ÃÀå, À¯Çüº°, 2020-2032³â

Á¦5Àå Àΰ£ °áÇÙ ¹é½Å ½ÃÀå, ¿¬·ÉÃþº°, 2020-2032³â

Á¦6Àå Àΰ£ °áÇÙ ¹é½Å ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â

Á¦7Àå Àΰ£ °áÇÙ ¹é½Å ½ÃÀå, Áö¿ªº°, 2020-2032³â, °¡Ä¡

Á¦8Àå °æÀï ±¸µµ

Á¦9Àå ¾Ö³Î¸®½ºÆ®ÀÇ Ãßõ»çÇ×

Á¦10Àå Âü°í¹®Çå°ú Á¶»ç ¹æ¹ý

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Human Tuberculosis Vaccine Market is estimated to be valued at USD 68.1 Mn in 2025 and is expected to reach USD 102.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.0% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 68.1 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 6.00% 2032 Value Projection: USD 102.4 Mn
Figure. Human Tuberculosis Vaccine Market Share (%), By Region 2025
Human Tuberculosis Vaccine Market - IMG1

Tuberculosis remains one of the top 10 causes of death worldwide, despite being a curable and preventable disease. Currently, the only widely used TB vaccine is the Bacille Calmette-Guerin (BCG) vaccine, which provides limited protection and is only recommended for children. There is an urgent need for new, effective vaccines to control the global TB burden. Several candidate vaccines are in clinical trials, targeting different stages of the Mycobacterium tuberculosis lifecycle. Vaccines that provide lasting protection against pulmonary TB disease and transmission could be a game changer in the effort to eliminate this ancient pathogen.

Market Dynamics:

The global human tuberculosis vaccine market is primarily driven by the persistent burden of TB disease worldwide. On October 29, 2025, according to the WHO, a total of 1.25 million people died from tuberculosis (TB) in 2025. Worldwide, TB has probably returned to being the world's leading cause of death from a single infectious agent, following three years in which it was replaced by coronavirus disease (COVID-19). The need for improved diagnostics and vaccines has spurred heavy investments from global health organizations into TB vaccine R&D. Over 15 vaccine candidates are currently in clinical trials of different phases. However, high development costs and regulatory hurdles pose challenges. Scientists are exploring new technologies like mRNA platforms to improve the efficacy, safety, and ease of manufacture of tuberculosis vaccines. Asia Pacific is the largest market due to high TB prevalence in countries like India and China. Developing an effective vaccine could potentially curb disease transmission and generate substantial savings for overburdened healthcare systems.

Key Features of the Study:

This report provides in-depth analysis of the global human tuberculosis vaccine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global human tuberculosis vaccine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include GSK plc., Serum Institute of India Pvt. Ltd., Valneva SE, Archivel Farma, BIOFABRI (Zendal), Japan BCG Laboratory, CSL Seqirus, GreenSignal Bio Pharma Private Limited (GSBPL), AJ Vaccines A/S, Taj Pharmaceuticals Ltd., Merck & Co., Inc., Bharat Biotech, Moderna, Inc., and BioNTech SE

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global human tuberculosis vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human tuberculosis vaccine market

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Human Tuberculosis Vaccine Market, By Type, 2020-2032, (USD Mn)

5. Human Tuberculosis Vaccine Market, By Age Group, 2020-2032, (USD Mn)

6. Human Tuberculosis Vaccine Market, By Distribution Channel, 2020-2032, (USD Mn)

7. Human Tuberculosis Vaccine Market, By Region, 2020 - 2032, Value (USD Mn)

8. Competitive Landscape

9. Analyst Recommendations

10. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â